ANI Pharmaceuticals: The Market Is Pricing The Present, Not The Future

Impact · against what's priced in

ANI Pharmaceuticals presents a bullish case based on 2027 growth that the current valuation is failing to capture. While 2026 margins will suffer due to gout expansion costs and royalties, the projected upside from these initiatives creates a disconnect between the current $80 price and a $95 fair value target.

ANIP+0.60

No priced-in read yet

In context

The market is currently valuing the stock at ~$80, which fails to account for the 2027 earnings potential driven by the new gout initiative. While 2026 results will be weighed down by upfront costs and royalties, the long-term operating leverage suggests a fair value of $95.

Read from the article alone

• revenue growth▲8%
• pharmaceuticals▲6%
• healthcare
• valuation
• ANIP
• earnings forecast
• price target

Top 2 movers · tap to explore